Mar 22 |
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
|
Mar 19 |
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
|
Mar 16 |
Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results
|
Mar 15 |
Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?
|
Mar 14 |
Monte Rosa Therapeutics GAAP EPS of -$0.58
|
Mar 14 |
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Mar 11 |
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
|
Feb 15 |
Monte Rosa draws bullish view at Wedbush on protein degradation
|
Jan 16 |
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
|
Jan 8 |
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
|